FORT WASHINGTON, Pa.--(BUSINESS WIRE)--While therapeutic advances have improved survival of patients with follicular lymphoma (FL), it remains an incurable disease with inevitable relapse. This underscores the need for therapies and strategies to extend the duration of remission without significantly increasing toxicity and while maintaining quality of life. The role of maintenance therapies in FL was discussed in detail by Andrew D. Zelenetz, MD, PhD, of Memorial Sloan-Kettering Cancer Center and chair of the NCCN Guidelines Panel for Non-Hodgkin’s Lymphomas during the NCCN 6th Annual Congress: Hematologic Malignancies™.
